Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenecteplase vs Standard Treatment for Acute Ischemic Stroke (TRACE III)
NCT05141305Phase 3Completed
- Sponsor
- Beijing Tiantan Hospital
- Start
- Jan 2022
- Primary completion
- Jan 2024
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 3 trial of tenecteplase in acute ischemic stroke (AIS), sponsored by Beijing Tiantan Hospital. Started Jan 2022; status: completed.
02
Drugs
tenecteplase
03
Conditions
acute ischemic stroke (AIS)
Beyond the preview
Go deeper on NCT05141305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05141305.